Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis. OBJECTIVES: To evaluate the impact of apremilast on health‐related quality of life (HRQOL), general functioning and mental healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R., Feldman, S.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363239/
https://www.ncbi.nlm.nih.gov/pubmed/27538241
http://dx.doi.org/10.1111/jdv.13918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363239/
https://www.ncbi.nlm.nih.gov/pubmed/27538241
http://dx.doi.org/10.1111/jdv.13918

Ejemplares similares